News By Tag * Epilepsy * Childhood * Therapeutic * Pipeline * Clinical * Trial * Therapeutics * 2011-2019 * Cns * Sponsors * More Tags... Industry News News By Place Country(s) Industry News
|  Just Released: "Childhood Epilepsy Therapeutics -Pipeline Assessment and Market Forecasts to 2019"New Pharmaceuticals research report from GlobalData is now available from Fast Market Research
By: Fast Market Research, Inc. ------------------------------------------------------------ Full Report Details at - http://www.fastmr.com/ ------------------------------------------------------------ Scope The report provides information on the key drivers and challenges of the Childhood Epilepsy Therapeutics market. Its scope includes - * Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Childhood Epilepsy Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. * Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes. * Analysis of the current and future competition in the seven key countries Childhood Epilepsy Therapeutics market. * Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. * Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Childhood Epilepsy Therapeutics market. * Analysis of key recent licensing and partnership agreements in Childhood Epilepsy Therapeutics market Reasons to buy The report will enhance your decision making capability. It will allow you to - * Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. * Develop business strategies by understanding the trends shaping and driving the global Childhood Epilepsy Therapeutics market. * Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Childhood Epilepsy Therapeutics market in future. * Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. * Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. * Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. * What's the next big thing in the global Childhood Epilepsy Therapeutics market landscape? - Identify, understand and capitalize. Companies Mentioned in this Report: UCB S.A., Supernus Pharmaceuticals, Eisai Co., Ltd., Kirin Holdings Company, Limited, GlaxoSmithKline plc, Pfizer, Bial Portela C.S.A. Partial Table of Contents: 1 Table of Contents 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Childhood Epilepsy Therapeutics - Introduction 2.1 Overview 2.1.1 Types of Epilepsy 2.1.2 Childhood Epilepsy Syndromes 2.2 Etiology and Pathophysiology 2.3 Epidemiology 2.3.1 The US 2.3.2 EU 2.3.3 Japan 2.3.4 Health Related Quality of Life (HRQoL) 2.4 Symptoms 2.5 Diagnosis 2.5.1 Tests 2.6 Treatment and Management Pattern 2.6.1 Pharmacological Treatment 2.6.2 Ketogenic Diet 2.6.3 Epilepsy Surgery 2.7 Referral Pathway 2.8 GlobalData Pipeline Report Guidance 3 Childhood Epilepsy Therapeutics - Market Characterization 3.1 Overview 3.2 Childhood Epilepsy Therapeutics Market Size (2006-2011) - Global 3.3 Childhood Epilepsy Therapeutics Market Forecast (2011 - 2019) - Global 3.4 Childhood Epilepsy Therapeutics Market Size (2006 - 2011) - The US 3.5 Childhood Epilepsy Therapeutics Market Forecast (2011 - 2019) - The US 3.6 Childhood Epilepsy Therapeutics Market Size (2006 - 2011) - France 3.7 Childhood Epilepsy Therapeutics Market Forecast (2011 - 2019) - France 3.8 Childhood Epilepsy Therapeutics Market Size (2006 - 2011) - Germany 3.9 Childhood Epilepsy Therapeutics Market Forecast (2011-2019) - Germany 3.10 Childhood Epilepsy Therapeutics Market Size (2006-2011) - Italy 3.11 Childhood Epilepsy Therapeutics Market Forecast (2011 - 2019) - Italy 3.12 Childhood Epilepsy Therapeutics Market Size (2006 - 2011) - Spain 3.13 Childhood Epilepsy Therapeutics Market Forecast (2011 - 2019) - Spain 3.14 Childhood Epilepsy Therapeutics Market Size (2006-2011) - The UK 3.15 Childhood Epilepsy Therapeutics Market Forecast (2011 - 2019) - The UK 3.16 Childhood Epilepsy Therapeutics Market Size (2006-2011) - Japan 3.17 Childhood Epilepsy Therapeutics Market Forecast (2011 - 2019) - Japan 3.18 Drivers and Barriers 3.18.1 Drivers for Childhood Epilepsy Therapeutics Market 3.18.2 Barriers for the Childhood Epilepsy Therapeutics Market 3.19 Opportunity and Unmet Needs 3.20 Key Takeaway 4 Childhood Epilepsy Therapeutics Market - Competitive Assessment 4.1 Overview 4.2 Strategic Competitor Assessment 4.3 Product Profile for the Major Marketed Products in the Childhood Epilepsy Disorders Therapeutics market 4.3.1 Lamictal (lamotrigine) Full Table of Contents is available at: -- http://www.fastmr.com/ About GlobalData GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at http://www.fastmr.com/ End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number